With diabetes and other diseases at epidemic levels, the need for more pharmacies to step up and offer accessible, convenient patient screening for a variety of serious and even life-threatening conditions is clear, a panel of pharmacists asserted at the NACDS Total Store Expo “Convenient Care — Point of Care Testing in the Pharmacy” Insight Session in late August. So, too, is the opportunity to drive new business to the pharmacy through point-of-care testing services.
Thanks to the Centers for Medicare and Medicaid Services’ Five-Star Quality Rating System, the diabetes community stands to play a significant role in how pharmacies think about their patients and their medication adherence programs.
The Department of Justice announced Friday that it filed a motion to hold Bayer in civil contempt for violating a court order in the U.S. District Court for the District of New Jersey.
Medivation and Astellas Pharma on Wednesday announced that the Food and Drug Administration approved a new use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer.
The Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as a chronic weight-management option.
Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global.
The National Association of Chain Drug Stores has announced that NACDS-backed bipartisan legislation, H.R. 4190, which would expand pharmacists’ ability to serve patients and improve their healthcare outcomes, has garnered a milestone 100 co-sponsors.
The Food and Drug Administration recently announced the availability of the “Purple Book,” which lists biological products in much the same way that the "Orange Book" lists pharmaceuticals.
America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention.
Silvergate Pharmaceuticals on Monday announced that the Food and Drug Administration approved Epaned (enalapril maleate Powder for oral solution) for the treatment of symptomatic heart failure, as well as the treatment of asymptomatic left ventricular dysfunction.